1
项与 Anti-CD22-CAR T cell therapy(Kecellitics Biotech Company Ltd) 相关的临床试验Phase I Study of T Cells Expressing an Anti-CD22 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
This study aims to evaluate the safety, efficacy and duration of response of CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD22+ haematological malignancies.
100 项与 Anti-CD22-CAR T cell therapy(Kecellitics Biotech Company Ltd) 相关的临床结果
100 项与 Anti-CD22-CAR T cell therapy(Kecellitics Biotech Company Ltd) 相关的转化医学
100 项与 Anti-CD22-CAR T cell therapy(Kecellitics Biotech Company Ltd) 相关的专利(医药)
100 项与 Anti-CD22-CAR T cell therapy(Kecellitics Biotech Company Ltd) 相关的药物交易